Kymriah approval generates questions about cost, access, long-term impact of CAR T-cell therapy – Healio
OncLive |
Kymriah approval generates questions about cost, access, long-term impact of CAR T-cell therapy
Healio The recent FDA approval of tisagenlecleucel T-suspension for the treatment of children and young adults with refractory B-cell precursor acute lymphoblastic leukemia marks the first-ever chimeric antigen receptor (CAR) T-cell therapy approval in the … Monroe Carell Jr. Children's Hospital at Vanderbilt to offer new cutting-edge treatment for type of pediatric leukemia |
